Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
National Cancer Institute (NCI)
Bayer
Memorial Sloan Kettering Cancer Center
Arcus Biosciences, Inc.
Memorial Sloan Kettering Cancer Center
Sotio Biotech Inc.
Eli Lilly and Company
Rondo Therapeutics
BeOne Medicines
ViroMissile, Inc.
AstraZeneca
Tizona Therapeutics, Inc
Essen Biotech
Clasp Therapeutics, Inc.
Brigham and Women's Hospital
Baylor College of Medicine
University of Colorado, Denver
MacroGenics
Institut Bergonié
City of Hope Medical Center
Daiichi Sankyo
Second Life Therapeutics
Ocellaris Pharma, Inc.
Medical College of Wisconsin
Var2 Pharmaceuticals
OncoNano Medicine, Inc.
Mayo Clinic
NeoTX Therapeutics Ltd.
BicycleTx Limited
BicycleTx Limited
UNC Lineberger Comprehensive Cancer Center
Actym Therapeutics, Inc.
Institut Bergonié
University of Colorado, Denver
Shanghai Escugen Biotechnology Co., Ltd
Washington University School of Medicine
Västernorrland County Council, Sweden
Palleon Pharmaceuticals, Inc.
Sensei Biotherapeutics, Inc.
Merck Sharp & Dohme LLC
Jonsson Comprehensive Cancer Center
Cancer Research UK
University of California, San Francisco
Incyte Corporation
UNC Lineberger Comprehensive Cancer Center
Medicenna Therapeutics, Inc.
Genentech, Inc.
TransThera Sciences (Nanjing), Inc.